Author:
Espí Alejandro,Arenas Javier,García-Granero Eduardo,Martí Elena,Lledó Salvador
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology,General Medicine
Reference20 articles.
1. Rosenberg SA, Lotze MT, Muul LM,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92.
2. Mule JJ, Yang J, Shu S, Rosenberg SA. The anti-tumour efficacy of lymphokine-activated killer cells and recombinant interleukin 2in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 1986;136:3899–909.
3. Hawkins MJ, Atkins MB, Dutcher JP,et al. A phase II clinical trial of interleukin 2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother 1994;15:74–8.
4. Steis RG, Urba WJ, Van der Molen LA,et al. Intraperitoneal lymphokine-activated killer cell and interleukin 2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 1990;8:1618–29.
5. Parks KG, Heys SD, Murray JB,et al. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity. Cancer Immunol Immunother 1992;35:53–8.
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献